A recent study looked at the difference in immune cell infiltrates across HER2-positive, HER2-negatve, and HER2-low tumours in EGA, and found that HER2-low tumours had significantly greater immune cell infiltration compared with HER2-positive tumours, suggesting a more inflamed and immunogenic tumour immune microenvironment (TIME) [63]. The gene discussed is ERBB2; the disease is neoplasm.